Episode description

This panel was recorded 21 November 2024. Please join us live for future shows for the chance to participate in the chat and ask your own questions! You can sign up for these events and see more free thought leadership content in the ⁠⁠⁠⁠⁠⁠⁠⁠⁠Knowledge Center⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠at RQMplus.com.

Thank you for tuning in. 🙏

As significant changes to ISO 10993-1 loom on the horizon, manufacturers across MedTech are seeking clarity on what's coming and how to prepare. Join our expert panel for an essential discussion on these upcoming revisions to ISO 10993-1 and their far-reaching implications for biological evaluation processes.

Our panel will provide actionable insights into:

• The most significant upcoming changes to ISO 10993-1 and their implementation timeline
• Comprehensive guidance on applying the ISO 14971 device risk management framework to biological evaluation, including, new approaches to risk estimation, considerations for reasonably foreseeable misuse, practical implementation strategies

• Critical updates to device categorization and their impact on modified biological effects
• Strategic considerations for maintaining compliance during

Panelists:

• Taryn Meade – Director of Biological Evaluation
• Stephen Bond – Senior Toxicologist
• Amanda DeGraw, MS, Ph.D., DABT – Principal Toxicologist

Moderator:

• Christine Santagate, RAC – Vice President of Lab Services 

Topics with Timestamps:

00:00 Introduction to RQM+ and ISO 10993-1

02:53 Overview of ISO 10993-1 Updates

05:50 Key Changes in Biological Evaluation

08:23 Device Classification and Contact Duration

10:45 Implementation Timeline and Regulatory Considerations

13:32 Risk Estimation and Biological Evaluation

16:41 FDA Guidance and Non-Harmonization Issues

29:09 Navigating Device Categorization and FDA Feedback

31:18 Balancing Testing Burdens and Biological Safety

33:14 Understanding Reasonably Foreseeable Misuse

35:45 Challenges in Risk Assessment and Off-Label Use

39:49 Implementing ISO 14971 in Biological Evaluation

41:31 Modified Biological Effects and Device Categorization

43:31 Addressing Repeated Use of Single-Use Devices

47:16 In-House vs. Outsourced Testing for E&L

50:47 Key Advice for Manufacturers on Upcoming Changes

--

📲 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow RQM+ on LinkedIn.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

💼 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out our open positions.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

📚 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠See on-demand content in our Knowledge Center.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

📝 If you'd like to speak with us directly about how we might be able to support you and your organization, you're welcome to use ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠our contact form⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.